Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction
dc.contributor.author | SURYONO, Suryono | |
dc.contributor.author | ROHMAN, Mohammad Saifur | |
dc.contributor.author | WIDJAJANTO, Edi | |
dc.contributor.author | PRAYITNANINGSIH, Seskoati | |
dc.contributor.author | WIHASTUTI, Titin Andri | |
dc.contributor.author | OKTAVIONO, Yudi Her | |
dc.date.accessioned | 2023-10-10T06:11:59Z | |
dc.date.available | 2023-10-10T06:11:59Z | |
dc.date.issued | 2023-09-11 | |
dc.identifier.uri | https://repository.unej.ac.id/xmlui/handle/123456789/118209 | |
dc.description.abstract | According to WHO 2020, CAD is the second leading cause of death in Indonesia with death cases reaching 259,297 or 15.33% of total deaths. Unfortunately, most of the patients of CAD in Indonesia did not match the golden period or decline to be treated with Percutaneous Coronary Intervention (PCI). Based on the recent study, there were increases in MMP-9, NOX2, and TGF-β1 in STEMI patients which contribute to cardiac remodeling. Moreover, there is controversy regarding the benefit of late PCI (12-48 hours after onset of STEMI) in stable patients. Lately, colchicine is widely used in cardiovascular disease. This study was conducted to explore the effect of colchicine to reduce MMP- 9, NOX2, and TGF-β1 levels after myocardial infarction in stable patients. | en_US |
dc.language.iso | en | en_US |
dc.publisher | BMC Cardiovascular Disorders | en_US |
dc.subject | Colchicine | en_US |
dc.subject | MMP-9 | en_US |
dc.subject | NOX2 | en_US |
dc.subject | PCI | en_US |
dc.subject | STEMI | en_US |
dc.subject | TGF-β1 | en_US |
dc.title | Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction | en_US |
dc.type | Article | en_US |
Files in this item
This item appears in the following Collection(s)
-
LSP-Jurnal Ilmiah Dosen [7301]
Koleksi Jurnal Ilmiah Dosen